Estudo randomizado | Nivolumabe vs. placebo em pacientes com mesotelioma maligno recidivante.
21 Out, 2021 | 11:10h
Comentário no Twitter
CONFIRM Trial: a phase III study demonstrated longer PFS and OS with Nivolumab compared with Placebo in patients with Pleural or Peritoneal Malignant Mesothelioma who have progressed following platinum-based chemotherapy @OncoAlert #LCSM https://t.co/jKoKXEXgpB
— Dipesh Uprety MD FACP (@dipeshuprety4) October 15, 2021